#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=8 .
1-1	0-1	8	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Complications of LVADs
2-1	4-17	Complications	abstract[2]	new[2]	coref	5-1[15_2]
2-2	18-20	of	abstract[2]	new[2]	_	_
2-3	21-26	LVADs	abstract[2]|abstract	new[2]|new	coref	6-14

#Text=While survival has improved with CF-LVADS , the adverse event profile remains high .
3-1	27-32	While	_	_	_	_
3-2	33-41	survival	event	new	_	_
3-3	42-45	has	_	_	_	_
3-4	46-54	improved	_	_	_	_
3-5	55-59	with	_	_	_	_
3-6	60-68	CF-LVADS	substance	new	_	_
3-7	69-70	,	_	_	_	_
3-8	71-74	the	abstract[7]	new[7]	_	_
3-9	75-82	adverse	abstract[7]	new[7]	_	_
3-10	83-88	event	event|abstract[7]	new|new[7]	_	_
3-11	89-96	profile	abstract[7]	new[7]	_	_
3-12	97-104	remains	_	_	_	_
3-13	105-109	high	_	_	_	_
3-14	110-111	.	_	_	_	_

#Text=At 1 month post-implant , nearly 30 % and at 1 year , almost 80 % of patients , require readmission .
4-1	112-114	At	_	_	_	_
4-2	115-116	1	time[8]|object[9]	new[8]|new[9]	_	_
4-3	117-122	month	time[8]|object[9]	new[8]|new[9]	_	_
4-4	123-135	post-implant	object[9]	new[9]	_	_
4-5	136-137	,	_	_	_	_
4-6	138-144	nearly	quantity[10]	new[10]	_	_
4-7	145-147	30	quantity[10]	new[10]	_	_
4-8	148-149	%	quantity[10]	new[10]	_	_
4-9	150-153	and	_	_	_	_
4-10	154-156	at	_	_	_	_
4-11	157-158	1	time[11]|quantity[12]	new[11]|new[12]	_	_
4-12	159-163	year	time[11]|quantity[12]	new[11]|new[12]	_	_
4-13	164-165	,	quantity[12]	new[12]	_	_
4-14	166-172	almost	quantity[12]	new[12]	_	_
4-15	173-175	80	quantity[12]	new[12]	_	_
4-16	176-177	%	quantity[12]	new[12]	_	_
4-17	178-180	of	quantity[12]	new[12]	_	_
4-18	181-189	patients	quantity[12]|person	new[12]|new	coref	6-12[22_0]
4-19	190-191	,	_	_	_	_
4-20	192-199	require	_	_	_	_
4-21	200-211	readmission	abstract	new	_	_
4-22	212-213	.	_	_	_	_

#Text=The common LVAD-related complications , outside of the immediate post-operative period , are outlined in Table 4 .
5-1	214-217	The	abstract[15]	giv[15]	coref	7-4[26_15]
5-2	218-224	common	abstract[15]	giv[15]	_	_
5-3	225-237	LVAD-related	abstract[15]	giv[15]	_	_
5-4	238-251	complications	abstract[15]	giv[15]	_	_
5-5	252-253	,	abstract[15]	giv[15]	_	_
5-6	254-261	outside	abstract[15]	giv[15]	_	_
5-7	262-264	of	abstract[15]	giv[15]	_	_
5-8	265-268	the	abstract[15]|time[16]	giv[15]|new[16]	_	_
5-9	269-278	immediate	abstract[15]|time[16]	giv[15]|new[16]	_	_
5-10	279-293	post-operative	abstract[15]|time[16]	giv[15]|new[16]	_	_
5-11	294-300	period	abstract[15]|time[16]	giv[15]|new[16]	_	_
5-12	301-302	,	_	_	_	_
5-13	303-306	are	_	_	_	_
5-14	307-315	outlined	_	_	_	_
5-15	316-318	in	_	_	_	_
5-16	319-324	Table	abstract|abstract[18]	new|new[18]	_	_
5-17	325-326	4	abstract[18]	new[18]	_	_
5-18	327-328	.	_	_	_	_

#Text=Providers in the community may be the first medical contact for patients with LVADs experiencing a complication .
6-1	329-338	Providers	person[19]	new[19]	_	_
6-2	339-341	in	person[19]	new[19]	_	_
6-3	342-345	the	person[19]|place[20]	new[19]|new[20]	_	_
6-4	346-355	community	person[19]|place[20]	new[19]|new[20]	_	_
6-5	356-359	may	_	_	_	_
6-6	360-362	be	_	_	_	_
6-7	363-366	the	abstract[21]	new[21]	_	_
6-8	367-372	first	abstract[21]	new[21]	_	_
6-9	373-380	medical	abstract[21]	new[21]	_	_
6-10	381-388	contact	abstract[21]	new[21]	_	_
6-11	389-392	for	abstract[21]	new[21]	_	_
6-12	393-401	patients	abstract[21]|person[22]	new[21]|giv[22]	coref	13-5[53_22]
6-13	402-406	with	abstract[21]|person[22]	new[21]|giv[22]	_	_
6-14	407-412	LVADs	abstract[21]|person[22]|object	new[21]|giv[22]|giv	coref	11-19
6-15	413-425	experiencing	_	_	_	_
6-16	426-427	a	abstract[24]	new[24]	_	_
6-17	428-440	complication	abstract[24]	new[24]	_	_
6-18	441-442	.	_	_	_	_

#Text=Though management of these complications should be in concert with LVAD specialists , an awareness and understanding of the common complications can help with timely diagnosis and therapeutic intervention .
7-1	443-449	Though	_	_	_	_
7-2	450-460	management	abstract[25]	new[25]	_	_
7-3	461-463	of	abstract[25]	new[25]	_	_
7-4	464-469	these	abstract[25]|abstract[26]	new[25]|giv[26]	coref	7-19[32_26]
7-5	470-483	complications	abstract[25]|abstract[26]	new[25]|giv[26]	_	_
7-6	484-490	should	_	_	_	_
7-7	491-493	be	_	_	_	_
7-8	494-496	in	_	_	_	_
7-9	497-504	concert	event[27]	new[27]	_	_
7-10	505-509	with	event[27]	new[27]	_	_
7-11	510-514	LVAD	event[27]|object|person[29]	new[27]|new|new[29]	coref|coref	9-1|9-1
7-12	515-526	specialists	event[27]|person[29]	new[27]|new[29]	_	_
7-13	527-528	,	_	_	_	_
7-14	529-531	an	abstract[30]	new[30]	_	_
7-15	532-541	awareness	abstract[30]	new[30]	_	_
7-16	542-545	and	_	_	_	_
7-17	546-559	understanding	abstract[31]	new[31]	_	_
7-18	560-562	of	abstract[31]	new[31]	_	_
7-19	563-566	the	abstract[31]|abstract[32]	new[31]|giv[32]	_	_
7-20	567-573	common	abstract[31]|abstract[32]	new[31]|giv[32]	_	_
7-21	574-587	complications	abstract[31]|abstract[32]	new[31]|giv[32]	_	_
7-22	588-591	can	_	_	_	_
7-23	592-596	help	_	_	_	_
7-24	597-601	with	_	_	_	_
7-25	602-608	timely	abstract[33]	new[33]	_	_
7-26	609-618	diagnosis	abstract[33]	new[33]	_	_
7-27	619-622	and	_	_	_	_
7-28	623-634	therapeutic	event[34]	new[34]	_	_
7-29	635-647	intervention	event[34]	new[34]	_	_
7-30	648-649	.	_	_	_	_

#Text=8.1 .
8-1	650-653	8.1	abstract	new	_	_
8-2	654-655	.	_	_	_	_

#Text=LVAD
9-1	656-660	LVAD	abstract	giv	coref	12-4[48_0]

#Text=Infections
10-1	661-671	Infections	abstract	new	coref	11-13

#Text=Due to the presence of a percutaneous driveline exiting the skin , infections remain the Achilles heel of LVADs .
11-1	672-675	Due	_	_	_	_
11-2	676-678	to	_	_	_	_
11-3	679-682	the	abstract[38]	new[38]	coref	20-30[128_38]
11-4	683-691	presence	abstract[38]	new[38]	_	_
11-5	692-694	of	abstract[38]	new[38]	_	_
11-6	695-696	a	abstract[38]|abstract[39]	new[38]|new[39]	coref	13-19[58_39]
11-7	697-709	percutaneous	abstract[38]|abstract[39]	new[38]|new[39]	_	_
11-8	710-719	driveline	abstract[38]|abstract[39]	new[38]|new[39]	_	_
11-9	720-727	exiting	_	_	_	_
11-10	728-731	the	object[40]	new[40]	coref	22-4[0_40]
11-11	732-736	skin	object[40]	new[40]	_	_
11-12	737-738	,	_	_	_	_
11-13	739-749	infections	event	giv	coref	13-3[51_0]
11-14	750-756	remain	_	_	_	_
11-15	757-760	the	abstract[43]	new[43]	_	_
11-16	761-769	Achilles	person|abstract[43]	new|new[43]	_	_
11-17	770-774	heel	abstract[43]	new[43]	_	_
11-18	775-777	of	abstract[43]	new[43]	_	_
11-19	778-783	LVADs	abstract[43]|abstract	new[43]|giv	coref	34-12
11-20	784-785	.	_	_	_	_

#Text=Recent implantation of the first-in-man totally implantable LVAD aims to minimize this risk .
12-1	786-792	Recent	event[45]	new[45]	_	_
12-2	793-805	implantation	event[45]	new[45]	_	_
12-3	806-808	of	event[45]	new[45]	_	_
12-4	809-812	the	event[45]|object[48]	new[45]|giv[48]	coref	13-5[0_48]
12-5	813-825	first-in-man	event[45]|person|object[48]	new[45]|new|giv[48]	_	_
12-6	826-833	totally	event[45]|abstract[47]|object[48]	new[45]|new[47]|giv[48]	_	_
12-7	834-845	implantable	event[45]|abstract[47]|object[48]	new[45]|new[47]|giv[48]	_	_
12-8	846-850	LVAD	event[45]|object[48]	new[45]|giv[48]	_	_
12-9	851-855	aims	_	_	_	_
12-10	856-858	to	_	_	_	_
12-11	859-867	minimize	_	_	_	_
12-12	868-872	this	abstract[49]	new[49]	coref	16-14[91_49]
12-13	873-877	risk	abstract[49]	new[49]	_	_
12-14	878-879	.	_	_	_	_

#Text=ISHLT classifies infections in LVAD patients as VAD-specific ( involving the pump , cannula , pocket , or percutaneous driveline ) , VAD-related ( infective endocarditis , blood stream infections including central venous catheter associated , mediastinitis ) and non-VAD infections such as pneumonia .
13-1	880-885	ISHLT	organization	new	_	_
13-2	886-896	classifies	_	_	_	_
13-3	897-907	infections	event[51]	giv[51]	coref	13-28[61_51]
13-4	908-910	in	event[51]	giv[51]	_	_
13-5	911-915	LVAD	event[51]|abstract|person[53]	giv[51]|giv|giv[53]	coref|coref|coref|coref	18-24|21-13[138_53]|18-24|21-13[138_53]
13-6	916-924	patients	event[51]|person[53]	giv[51]|giv[53]	_	_
13-7	925-927	as	event[51]|person[53]	giv[51]|giv[53]	_	_
13-8	928-940	VAD-specific	event[51]|person[53]	giv[51]|giv[53]	_	_
13-9	941-942	(	_	_	_	_
13-10	943-952	involving	_	_	_	_
13-11	953-956	the	object[54]	new[54]	coref	31-4[0_54]
13-12	957-961	pump	object[54]	new[54]	_	_
13-13	962-963	,	_	_	_	_
13-14	964-971	cannula	object	new	_	_
13-15	972-973	,	_	_	_	_
13-16	974-980	pocket	object	new	_	_
13-17	981-982	,	_	_	_	_
13-18	983-985	or	_	_	_	_
13-19	986-998	percutaneous	person|abstract[58]	new|giv[58]	coref|coref	15-4[0_58]|15-4[0_58]
13-20	999-1008	driveline	abstract[58]	giv[58]	_	_
13-21	1009-1010	)	_	_	_	_
13-22	1011-1012	,	_	_	_	_
13-23	1013-1024	VAD-related	_	_	_	_
13-24	1025-1026	(	_	_	_	_
13-25	1027-1036	infective	abstract[59]	new[59]	_	_
13-26	1037-1049	endocarditis	abstract[59]	new[59]	_	_
13-27	1050-1051	,	_	_	_	_
13-28	1052-1057	blood	event[61]	giv[61]	coref	13-40[65_61]
13-29	1058-1064	stream	abstract|event[61]	new|giv[61]	_	_
13-30	1065-1075	infections	event[61]	giv[61]	_	_
13-31	1076-1085	including	event[61]	giv[61]	_	_
13-32	1086-1093	central	event[61]|object[63]	giv[61]|new[63]	_	_
13-33	1094-1100	venous	event[61]|person|object[63]	giv[61]|new|new[63]	_	_
13-34	1101-1109	catheter	event[61]|object[63]	giv[61]|new[63]	_	_
13-35	1110-1120	associated	_	_	_	_
13-36	1121-1122	,	_	_	_	_
13-37	1123-1136	mediastinitis	object	new	_	_
13-38	1137-1138	)	_	_	_	_
13-39	1139-1142	and	_	_	_	_
13-40	1143-1150	non-VAD	event[65]	giv[65]	coref	21-8[136_65]
13-41	1151-1161	infections	event[65]	giv[65]	_	_
13-42	1162-1166	such	event[65]	giv[65]	_	_
13-43	1167-1169	as	event[65]	giv[65]	_	_
13-44	1170-1179	pneumonia	event[65]|abstract	giv[65]|new	_	_
13-45	1180-1181	.	_	_	_	_

#Text=Different techniques , largely limited to single-center experiences , have been shown to reduce infection rates and there is no universal protocol .
14-1	1182-1191	Different	abstract[67]	new[67]	_	_
14-2	1192-1202	techniques	abstract[67]	new[67]	_	_
14-3	1203-1204	,	_	_	_	_
14-4	1205-1212	largely	_	_	_	_
14-5	1213-1220	limited	_	_	_	_
14-6	1221-1223	to	_	_	_	_
14-7	1224-1237	single-center	abstract[68]	new[68]	_	_
14-8	1238-1249	experiences	abstract[68]	new[68]	_	_
14-9	1250-1251	,	_	_	_	_
14-10	1252-1256	have	_	_	_	_
14-11	1257-1261	been	_	_	_	_
14-12	1262-1267	shown	_	_	_	_
14-13	1268-1270	to	_	_	_	_
14-14	1271-1277	reduce	_	_	_	_
14-15	1278-1287	infection	abstract|abstract[70]	new|new[70]	coref|coref	15-4[75_0]|15-4[75_0]
14-16	1288-1293	rates	abstract[70]	new[70]	_	_
14-17	1294-1297	and	_	_	_	_
14-18	1298-1303	there	_	_	_	_
14-19	1304-1306	is	_	_	_	_
14-20	1307-1309	no	abstract[71]	new[71]	_	_
14-21	1310-1319	universal	abstract[71]	new[71]	_	_
14-22	1320-1328	protocol	abstract[71]	new[71]	_	_
14-23	1329-1330	.	_	_	_	_

#Text=Risk factors for driveline infection include trauma to the driveline exit site , younger age , higher body mass index and exposed driveline velour .
15-1	1331-1335	Risk	person|abstract[73]	new|new[73]	_	_
15-2	1336-1343	factors	abstract[73]	new[73]	_	_
15-3	1344-1347	for	abstract[73]	new[73]	_	_
15-4	1348-1357	driveline	abstract[73]|abstract|abstract[75]	new[73]|giv|giv[75]	coref|coref|coref|coref	15-10|16-17[0_75]|15-10|16-17[0_75]
15-5	1358-1367	infection	abstract[73]|abstract[75]	new[73]|giv[75]	_	_
15-6	1368-1375	include	_	_	_	_
15-7	1376-1382	trauma	event[76]	new[76]	_	_
15-8	1383-1385	to	event[76]	new[76]	_	_
15-9	1386-1389	the	event[76]|place[79]	new[76]|new[79]	coref	16-1[86_79]
15-10	1390-1399	driveline	event[76]|abstract|place[79]	new[76]|giv|new[79]	coref	15-23
15-11	1400-1404	exit	event[76]|abstract|place[79]	new[76]|new|new[79]	coref	16-2
15-12	1405-1409	site	event[76]|place[79]	new[76]|new[79]	_	_
15-13	1410-1411	,	_	_	_	_
15-14	1412-1419	younger	abstract[80]	new[80]	coref	33-14[0_80]
15-15	1420-1423	age	abstract[80]	new[80]	_	_
15-16	1424-1425	,	_	_	_	_
15-17	1426-1432	higher	quantity[83]	new[83]	_	_
15-18	1433-1437	body	object|quantity[83]	new|new[83]	_	_
15-19	1438-1442	mass	quantity|quantity[83]	new|new[83]	_	_
15-20	1443-1448	index	quantity[83]	new[83]	_	_
15-21	1449-1452	and	_	_	_	_
15-22	1453-1460	exposed	_	_	_	_
15-23	1461-1470	driveline	abstract	giv	coref	16-5
15-24	1471-1477	velour	_	_	_	_
15-25	1478-1479	.	_	_	_	_

#Text=Meticulous exit site and driveline care and driveline immobilization are advised to reduce the risk of infection .
16-1	1480-1490	Meticulous	place[86]	giv[86]	coref	18-8[0_86]
16-2	1491-1495	exit	abstract|place[86]	giv|giv[86]	coref	24-8
16-3	1496-1500	site	place[86]	giv[86]	_	_
16-4	1501-1504	and	_	_	_	_
16-5	1505-1514	driveline	abstract|abstract[88]	giv|new[88]	coref|coref|coref|coref	16-8|18-30[0_88]|16-8|18-30[0_88]
16-6	1515-1519	care	abstract[88]	new[88]	_	_
16-7	1520-1523	and	_	_	_	_
16-8	1524-1533	driveline	abstract|event[90]	giv|new[90]	coref|coref	17-1|17-1
16-9	1534-1548	immobilization	event[90]	new[90]	_	_
16-10	1549-1552	are	_	_	_	_
16-11	1553-1560	advised	_	_	_	_
16-12	1561-1563	to	_	_	_	_
16-13	1564-1570	reduce	_	_	_	_
16-14	1571-1574	the	abstract[91]	giv[91]	_	_
16-15	1575-1579	risk	abstract[91]	giv[91]	_	_
16-16	1580-1582	of	abstract[91]	giv[91]	_	_
16-17	1583-1592	infection	abstract[91]|abstract	giv[91]|giv	coref	24-18[156_0]
16-18	1593-1594	.	_	_	_	_

#Text=Driveline drainage culture and blood cultures should be obtained , and imaging may be needed as well .
17-1	1595-1604	Driveline	abstract|abstract[95]	giv|new[95]	coref|coref|coref|coref	18-7|19-1[116_95]|18-7|19-1[116_95]
17-2	1605-1613	drainage	event|abstract[95]	new|new[95]	coref	18-14[105_0]
17-3	1614-1621	culture	abstract[95]	new[95]	_	_
17-4	1622-1625	and	_	_	_	_
17-5	1626-1631	blood	substance|object[97]	new|new[97]	coref|coref|coref|coref	21-1|21-1[134_97]|21-1|21-1[134_97]
17-6	1632-1640	cultures	object[97]	new[97]	_	_
17-7	1641-1647	should	_	_	_	_
17-8	1648-1650	be	_	_	_	_
17-9	1651-1659	obtained	_	_	_	_
17-10	1660-1661	,	_	_	_	_
17-11	1662-1665	and	_	_	_	_
17-12	1666-1673	imaging	event	new	_	_
17-13	1674-1677	may	_	_	_	_
17-14	1678-1680	be	_	_	_	_
17-15	1681-1687	needed	_	_	_	_
17-16	1688-1690	as	_	_	_	_
17-17	1691-1695	well	_	_	_	_
17-18	1696-1697	.	_	_	_	_

#Text=It is important to note that driveline site assessment and obtaining specimens of the drainage should only be performed by members of the LVAD team ( or designated shared care centers ) in order to limit the number of times and the number of people to whom the driveline is exposed .
18-1	1698-1700	It	abstract	new	cata	18-1[0_100]
18-2	1701-1703	is	_	_	_	_
18-3	1704-1713	important	_	_	_	_
18-4	1714-1716	to	abstract[100]	new[100]	_	_
18-5	1717-1721	note	abstract[100]	new[100]	_	_
18-6	1722-1726	that	abstract[100]	new[100]	_	_
18-7	1727-1736	driveline	abstract[100]|abstract|abstract[103]	new[100]|giv|new[103]	coref|coref	18-48[115_0]|18-48[115_0]
18-8	1737-1741	site	abstract[100]|place|abstract[103]	new[100]|giv|new[103]	coref	20-7[121_0]
18-9	1742-1752	assessment	abstract[100]|abstract[103]	new[100]|new[103]	_	_
18-10	1753-1756	and	abstract[100]	new[100]	_	_
18-11	1757-1766	obtaining	abstract[100]	new[100]	_	_
18-12	1767-1776	specimens	abstract[100]|object[104]	new[100]|new[104]	_	_
18-13	1777-1779	of	abstract[100]|object[104]	new[100]|new[104]	_	_
18-14	1780-1783	the	abstract[100]|object[104]|event[105]	new[100]|new[104]|giv[105]	coref	19-3[117_105]
18-15	1784-1792	drainage	abstract[100]|object[104]|event[105]	new[100]|new[104]|giv[105]	_	_
18-16	1793-1799	should	abstract[100]	new[100]	_	_
18-17	1800-1804	only	abstract[100]	new[100]	_	_
18-18	1805-1807	be	abstract[100]	new[100]	_	_
18-19	1808-1817	performed	abstract[100]	new[100]	_	_
18-20	1818-1820	by	_	_	_	_
18-21	1821-1828	members	person[106]	new[106]	_	_
18-22	1829-1831	of	person[106]	new[106]	_	_
18-23	1832-1835	the	person[106]|person[108]	new[106]|new[108]	coref	24-26[157_108]
18-24	1836-1840	LVAD	person[106]|event|person[108]	new[106]|giv|new[108]	coref	21-13
18-25	1841-1845	team	person[106]|person[108]	new[106]|new[108]	_	_
18-26	1846-1847	(	_	_	_	_
18-27	1848-1850	or	_	_	_	_
18-28	1851-1861	designated	place[110]	new[110]	_	_
18-29	1862-1868	shared	place[110]	new[110]	_	_
18-30	1869-1873	care	abstract|place[110]	giv|new[110]	_	_
18-31	1874-1881	centers	place[110]	new[110]	_	_
18-32	1882-1883	)	_	_	_	_
18-33	1884-1886	in	_	_	_	_
18-34	1887-1892	order	_	_	_	_
18-35	1893-1895	to	_	_	_	_
18-36	1896-1901	limit	_	_	_	_
18-37	1902-1905	the	time[111]	new[111]	_	_
18-38	1906-1912	number	time[111]	new[111]	_	_
18-39	1913-1915	of	time[111]	new[111]	_	_
18-40	1916-1921	times	time[111]|time	new[111]|new	_	_
18-41	1922-1925	and	_	_	_	_
18-42	1926-1929	the	quantity[113]	new[113]	_	_
18-43	1930-1936	number	quantity[113]	new[113]	_	_
18-44	1937-1939	of	quantity[113]	new[113]	_	_
18-45	1940-1946	people	quantity[113]|person[114]	new[113]|new[114]	_	_
18-46	1947-1949	to	quantity[113]|person[114]	new[113]|new[114]	_	_
18-47	1950-1954	whom	quantity[113]|person[114]	new[113]|new[114]	_	_
18-48	1955-1958	the	abstract[115]	giv[115]	coref	20-8[0_115]
18-49	1959-1968	driveline	abstract[115]	giv[115]	_	_
18-50	1969-1971	is	_	_	_	_
18-51	1972-1979	exposed	_	_	_	_
18-52	1980-1981	.	_	_	_	_

#Text=Culture of any drainage is recommended .
19-1	1982-1989	Culture	abstract[116]	giv[116]	_	_
19-2	1990-1992	of	abstract[116]	giv[116]	_	_
19-3	1993-1996	any	abstract[116]|event[117]	giv[116]|giv[117]	_	_
19-4	1997-2005	drainage	abstract[116]|event[117]	giv[116]|giv[117]	_	_
19-5	2006-2008	is	_	_	_	_
19-6	2009-2020	recommended	_	_	_	_
19-7	2021-2022	.	_	_	_	_

#Text=Abnormal swelling of the region surrounding the driveline site should be assessed by imaging studies ( i. e. , ultrasound , CT scan or PET scan ) to assess the presence , extent , and appearance of any fluid collections .
20-1	2023-2031	Abnormal	abstract[118]	new[118]	_	_
20-2	2032-2040	swelling	abstract[118]	new[118]	_	_
20-3	2041-2043	of	abstract[118]	new[118]	_	_
20-4	2044-2047	the	abstract[118]|place[119]	new[118]|new[119]	_	_
20-5	2048-2054	region	abstract[118]|place[119]	new[118]|new[119]	_	_
20-6	2055-2066	surrounding	_	_	_	_
20-7	2067-2070	the	place[121]	giv[121]	coref	24-6[154_121]
20-8	2071-2080	driveline	abstract|place[121]	giv|giv[121]	coref	24-7
20-9	2081-2085	site	place[121]	giv[121]	_	_
20-10	2086-2092	should	_	_	_	_
20-11	2093-2095	be	_	_	_	_
20-12	2096-2104	assessed	_	_	_	_
20-13	2105-2107	by	_	_	_	_
20-14	2108-2115	imaging	_	_	_	_
20-15	2116-2123	studies	event	new	coref	33-1[213_0]
20-16	2124-2125	(	_	_	_	_
20-17	2126-2128	i.	_	_	_	_
20-18	2129-2131	e.	_	_	_	_
20-19	2132-2133	,	_	_	_	_
20-20	2134-2144	ultrasound	abstract	new	_	_
20-21	2145-2146	,	_	_	_	_
20-22	2147-2149	CT	abstract|object[125]	new|new[125]	coref|coref	26-11[169_0]|26-11[169_0]
20-23	2150-2154	scan	object[125]	new[125]	_	_
20-24	2155-2157	or	_	_	_	_
20-25	2158-2161	PET	animal|object[127]	new|new[127]	coref|coref	27-7|27-7
20-26	2162-2166	scan	object[127]	new[127]	_	_
20-27	2167-2168	)	_	_	_	_
20-28	2169-2171	to	_	_	_	_
20-29	2172-2178	assess	_	_	_	_
20-30	2179-2182	the	abstract[128]	giv[128]	_	_
20-31	2183-2191	presence	abstract[128]	giv[128]	_	_
20-32	2192-2193	,	_	_	_	_
20-33	2194-2200	extent	abstract	new	coref	24-15[155_0]
20-34	2201-2202	,	_	_	_	_
20-35	2203-2206	and	_	_	_	_
20-36	2207-2217	appearance	abstract[130]	new[130]	_	_
20-37	2218-2220	of	abstract[130]	new[130]	_	_
20-38	2221-2224	any	abstract[130]|abstract[132]	new[130]|new[132]	_	_
20-39	2225-2230	fluid	abstract[130]|substance|abstract[132]	new[130]|new|new[132]	_	_
20-40	2231-2242	collections	abstract[130]|abstract[132]	new[130]|new[132]	_	_
20-41	2243-2244	.	_	_	_	_

#Text=Blood cultures are important to evaluate for occult bloodstream infections , because LVAD patients may not present with typical signs and symptoms .
21-1	2245-2250	Blood	person|object[134]	giv|giv[134]	_	_
21-2	2251-2259	cultures	object[134]	giv[134]	_	_
21-3	2260-2263	are	_	_	_	_
21-4	2264-2273	important	_	_	_	_
21-5	2274-2276	to	_	_	_	_
21-6	2277-2285	evaluate	_	_	_	_
21-7	2286-2289	for	_	_	_	_
21-8	2290-2296	occult	event[136]	giv[136]	coref	23-10[149_136]
21-9	2297-2308	bloodstream	object|event[136]	new|giv[136]	coref	37-1
21-10	2309-2319	infections	event[136]	giv[136]	_	_
21-11	2320-2321	,	_	_	_	_
21-12	2322-2329	because	_	_	_	_
21-13	2330-2334	LVAD	abstract|person[138]	giv|giv[138]	coref|coref|coref|coref	24-30|26-31[175_138]|24-30|26-31[175_138]
21-14	2335-2343	patients	person[138]	giv[138]	_	_
21-15	2344-2347	may	_	_	_	_
21-16	2348-2351	not	_	_	_	_
21-17	2352-2359	present	_	_	_	_
21-18	2360-2364	with	_	_	_	_
21-19	2365-2372	typical	abstract[139]	new[139]	_	_
21-20	2373-2378	signs	abstract[139]	new[139]	_	_
21-21	2379-2382	and	_	_	_	_
21-22	2383-2391	symptoms	abstract	new	_	_
21-23	2392-2393	.	_	_	_	_

#Text=Typical pathogens are skin flora like coagulase-negative Staphylococci and Staphylococcus aureus .
22-1	2394-2401	Typical	plant[141]	new[141]	coref	22-4[143_141]
22-2	2402-2411	pathogens	plant[141]	new[141]	_	_
22-3	2412-2415	are	_	_	_	_
22-4	2416-2420	skin	object|plant[143]	giv|giv[143]	_	_
22-5	2421-2426	flora	plant[143]	giv[143]	_	_
22-6	2427-2431	like	plant[143]	giv[143]	_	_
22-7	2432-2450	coagulase-negative	plant[143]|substance[144]	giv[143]|new[144]	_	_
22-8	2451-2464	Staphylococci	plant[143]|substance[144]	giv[143]|new[144]	_	_
22-9	2465-2468	and	plant[143]	giv[143]	_	_
22-10	2469-2483	Staphylococcus	plant[143]|abstract	giv[143]|new	_	_
22-11	2484-2490	aureus	plant[143]	giv[143]	_	_
22-12	2491-2492	.	_	_	_	_

#Text=Gram-negative organisms like Pseudomonas spp. and Enterobacteriaceae , and fungal infections can also occur .
23-1	2493-2506	Gram-negative	animal[146]	new[146]	coref	25-16[164_146]
23-2	2507-2516	organisms	animal[146]	new[146]	_	_
23-3	2517-2521	like	animal[146]	new[146]	_	_
23-4	2522-2533	Pseudomonas	animal[146]|place	new[146]|new	coref	30-10
23-5	2534-2538	spp.	animal[146]	new[146]	_	_
23-6	2539-2542	and	animal[146]	new[146]	_	_
23-7	2543-2561	Enterobacteriaceae	animal[146]|animal	new[146]|new	_	_
23-8	2562-2563	,	_	_	_	_
23-9	2564-2567	and	_	_	_	_
23-10	2568-2574	fungal	event[149]	giv[149]	coref	25-13[163_149]
23-11	2575-2585	infections	event[149]	giv[149]	_	_
23-12	2586-2589	can	_	_	_	_
23-13	2590-2594	also	_	_	_	_
23-14	2595-2600	occur	_	_	_	_
23-15	2601-2602	.	_	_	_	_

#Text=Surgical evaluation for debridement of the driveline exit site may be needed depending on the extent of the infection , and should be performed by a surgical team with LVAD experience .
24-1	2603-2611	Surgical	abstract[150]	new[150]	_	_
24-2	2612-2622	evaluation	abstract[150]	new[150]	_	_
24-3	2623-2626	for	abstract[150]	new[150]	_	_
24-4	2627-2638	debridement	abstract[150]|event[151]	new[150]|new[151]	coref	29-16[191_151]
24-5	2639-2641	of	abstract[150]|event[151]	new[150]|new[151]	_	_
24-6	2642-2645	the	abstract[150]|event[151]|place[154]	new[150]|new[151]|giv[154]	_	_
24-7	2646-2655	driveline	abstract[150]|event[151]|abstract|place[154]	new[150]|new[151]|giv|giv[154]	_	_
24-8	2656-2660	exit	abstract[150]|event[151]|abstract|place[154]	new[150]|new[151]|giv|giv[154]	_	_
24-9	2661-2665	site	abstract[150]|event[151]|place[154]	new[150]|new[151]|giv[154]	_	_
24-10	2666-2669	may	_	_	_	_
24-11	2670-2672	be	_	_	_	_
24-12	2673-2679	needed	_	_	_	_
24-13	2680-2689	depending	_	_	_	_
24-14	2690-2692	on	_	_	_	_
24-15	2693-2696	the	abstract[155]	giv[155]	_	_
24-16	2697-2703	extent	abstract[155]	giv[155]	_	_
24-17	2704-2706	of	abstract[155]	giv[155]	_	_
24-18	2707-2710	the	abstract[155]|abstract[156]	giv[155]|giv[156]	coref	26-28[174_156]
24-19	2711-2720	infection	abstract[155]|abstract[156]	giv[155]|giv[156]	_	_
24-20	2721-2722	,	_	_	_	_
24-21	2723-2726	and	_	_	_	_
24-22	2727-2733	should	_	_	_	_
24-23	2734-2736	be	_	_	_	_
24-24	2737-2746	performed	_	_	_	_
24-25	2747-2749	by	_	_	_	_
24-26	2750-2751	a	person[157]	giv[157]	_	_
24-27	2752-2760	surgical	person[157]	giv[157]	_	_
24-28	2761-2765	team	person[157]	giv[157]	_	_
24-29	2766-2770	with	person[157]	giv[157]	_	_
24-30	2771-2775	LVAD	person[157]|abstract|abstract[159]	giv[157]|giv|new[159]	coref|coref	33-6|33-6
24-31	2776-2786	experience	person[157]|abstract[159]	giv[157]|new[159]	_	_
24-32	2787-2788	.	_	_	_	_

#Text=Infectious diseases consultation may be needed , particularly in the case of polymicrobial infections or multidrug-resistant organisms .
25-1	2789-2799	Infectious	abstract[161]	new[161]	_	_
25-2	2800-2808	diseases	abstract|abstract[161]	new|new[161]	_	_
25-3	2809-2821	consultation	abstract[161]	new[161]	_	_
25-4	2822-2825	may	_	_	_	_
25-5	2826-2828	be	_	_	_	_
25-6	2829-2835	needed	_	_	_	_
25-7	2836-2837	,	_	_	_	_
25-8	2838-2850	particularly	abstract[162]	new[162]	_	_
25-9	2851-2853	in	abstract[162]	new[162]	_	_
25-10	2854-2857	the	abstract[162]	new[162]	_	_
25-11	2858-2862	case	abstract[162]	new[162]	_	_
25-12	2863-2865	of	abstract[162]	new[162]	_	_
25-13	2866-2879	polymicrobial	abstract[162]|event[163]	new[162]|giv[163]	coref	28-1[184_163]
25-14	2880-2890	infections	abstract[162]|event[163]	new[162]|giv[163]	_	_
25-15	2891-2893	or	abstract[162]|event[163]	new[162]|giv[163]	_	_
25-16	2894-2913	multidrug-resistant	abstract[162]|event[163]|animal[164]	new[162]|giv[163]|giv[164]	_	_
25-17	2914-2923	organisms	abstract[162]|event[163]|animal[164]	new[162]|giv[163]|giv[164]	_	_
25-18	2924-2925	.	_	_	_	_

#Text=If bacteremia or sepsis are present , a chest and abdomen CT , transthoracic and even transesophageal echocardiogram should be obtained to evaluate for the source of the infection ( especially in patients with pacemaker or defibrillator leads ) .
26-1	2926-2928	If	_	_	_	_
26-2	2929-2939	bacteremia	abstract	new	_	_
26-3	2940-2942	or	_	_	_	_
26-4	2943-2949	sepsis	abstract	new	_	_
26-5	2950-2953	are	_	_	_	_
26-6	2954-2961	present	_	_	_	_
26-7	2962-2963	,	_	_	_	_
26-8	2964-2965	a	object[167]	new[167]	_	_
26-9	2966-2971	chest	object[167]	new[167]	_	_
26-10	2972-2975	and	_	_	_	_
26-11	2976-2983	abdomen	place|abstract[169]	new|giv[169]	_	_
26-12	2984-2986	CT	abstract[169]	giv[169]	_	_
26-13	2987-2988	,	_	_	_	_
26-14	2989-3002	transthoracic	object	new	_	_
26-15	3003-3006	and	_	_	_	_
26-16	3007-3011	even	abstract[172]	new[172]	_	_
26-17	3012-3027	transesophageal	abstract|abstract[172]	new|new[172]	_	_
26-18	3028-3042	echocardiogram	abstract[172]	new[172]	_	_
26-19	3043-3049	should	_	_	_	_
26-20	3050-3052	be	_	_	_	_
26-21	3053-3061	obtained	_	_	_	_
26-22	3062-3064	to	_	_	_	_
26-23	3065-3073	evaluate	_	_	_	_
26-24	3074-3077	for	_	_	_	_
26-25	3078-3081	the	abstract[173]	new[173]	_	_
26-26	3082-3088	source	abstract[173]	new[173]	_	_
26-27	3089-3091	of	abstract[173]	new[173]	_	_
26-28	3092-3095	the	abstract[173]|abstract[174]	new[173]|giv[174]	coref	30-10[195_174]
26-29	3096-3105	infection	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
26-30	3106-3107	(	_	_	_	_
26-31	3108-3118	especially	person[175]	giv[175]	coref	32-37[0_175]
26-32	3119-3121	in	person[175]	giv[175]	_	_
26-33	3122-3130	patients	person[175]	giv[175]	_	_
26-34	3131-3135	with	person[175]	giv[175]	_	_
26-35	3136-3145	pacemaker	person[175]|object	giv[175]|new	_	_
26-36	3146-3148	or	person[175]	giv[175]	_	_
26-37	3149-3162	defibrillator	person[175]|abstract|abstract[178]	giv[175]|new|new[178]	_	_
26-38	3163-3168	leads	person[175]|abstract[178]	giv[175]|new[178]	_	_
26-39	3169-3170	)	_	_	_	_
26-40	3171-3172	.	_	_	_	_

#Text=There is an emerging role for PET imaging with F-18 labeled fluoro-2-deoxyglucose .
27-1	3173-3178	There	_	_	_	_
27-2	3179-3181	is	_	_	_	_
27-3	3182-3184	an	abstract[179]	new[179]	coref	31-1[198_179]
27-4	3185-3193	emerging	abstract[179]	new[179]	_	_
27-5	3194-3198	role	abstract[179]	new[179]	_	_
27-6	3199-3202	for	abstract[179]	new[179]	_	_
27-7	3203-3206	PET	abstract[179]|animal	new[179]|giv	_	_
27-8	3207-3214	imaging	_	_	_	_
27-9	3215-3219	with	_	_	_	_
27-10	3220-3224	F-18	object	new	_	_
27-11	3225-3232	labeled	_	_	_	_
27-12	3233-3254	fluoro-2-deoxyglucose	object	new	_	_
27-13	3255-3256	.	_	_	_	_

#Text=VAD infections are biofilm-based and difficult to eradicate .
28-1	3257-3260	VAD	object|event[184]	new|giv[184]	coref|coref|coref|coref	29-4|29-4[188_184]|29-4|29-4[188_184]
28-2	3261-3271	infections	event[184]	giv[184]	_	_
28-3	3272-3275	are	_	_	_	_
28-4	3276-3289	biofilm-based	_	_	_	_
28-5	3290-3293	and	_	_	_	_
28-6	3294-3303	difficult	_	_	_	_
28-7	3304-3306	to	_	_	_	_
28-8	3307-3316	eradicate	_	_	_	_
28-9	3317-3318	.	_	_	_	_

#Text=Treatment strategies for VAD infections include intravenous antibiotics followed by oral suppression in tandem with surgical debridement .
29-1	3319-3328	Treatment	person|abstract[186]	new|new[186]	_	_
29-2	3329-3339	strategies	abstract[186]	new[186]	_	_
29-3	3340-3343	for	abstract[186]	new[186]	_	_
29-4	3344-3347	VAD	abstract[186]|object|event[188]	new[186]|giv|giv[188]	coref|coref	30-1[0_188]|30-1[0_188]
29-5	3348-3358	infections	abstract[186]|event[188]	new[186]|giv[188]	_	_
29-6	3359-3366	include	_	_	_	_
29-7	3367-3378	intravenous	substance[189]	new[189]	_	_
29-8	3379-3390	antibiotics	substance[189]	new[189]	_	_
29-9	3391-3399	followed	_	_	_	_
29-10	3400-3402	by	_	_	_	_
29-11	3403-3407	oral	abstract[190]	new[190]	_	_
29-12	3408-3419	suppression	abstract[190]	new[190]	_	_
29-13	3420-3422	in	abstract[190]	new[190]	_	_
29-14	3423-3429	tandem	abstract[190]	new[190]	_	_
29-15	3430-3434	with	abstract[190]	new[190]	_	_
29-16	3435-3443	surgical	abstract[190]|event[191]	new[190]|giv[191]	coref	30-7[0_191]
29-17	3444-3455	debridement	abstract[190]|event[191]	new[190]|giv[191]	_	_
29-18	3456-3457	.	_	_	_	_

#Text=Infections tend to be recurrent despite debridement , with Pseudomonas infection in particular , showing a lower success rate .
30-1	3458-3468	Infections	event	giv	coref	33-6[215_0]
30-2	3469-3473	tend	_	_	_	_
30-3	3474-3476	to	_	_	_	_
30-4	3477-3479	be	_	_	_	_
30-5	3480-3489	recurrent	_	_	_	_
30-6	3490-3497	despite	_	_	_	_
30-7	3498-3509	debridement	event	giv	_	_
30-8	3510-3511	,	_	_	_	_
30-9	3512-3516	with	_	_	_	_
30-10	3517-3528	Pseudomonas	object|abstract[195]	giv|giv[195]	coref|coref	34-9[0_195]|34-9[0_195]
30-11	3529-3538	infection	abstract[195]	giv[195]	_	_
30-12	3539-3541	in	abstract[195]	giv[195]	_	_
30-13	3542-3552	particular	abstract[195]	giv[195]	_	_
30-14	3553-3554	,	_	_	_	_
30-15	3555-3562	showing	_	_	_	_
30-16	3563-3564	a	quantity[197]	new[197]	coref	34-5[222_197]
30-17	3565-3570	lower	quantity[197]	new[197]	_	_
30-18	3571-3578	success	abstract|quantity[197]	new|new[197]	_	_
30-19	3579-3583	rate	quantity[197]	new[197]	_	_
30-20	3584-3585	.	_	_	_	_

#Text=The role of pump exchange is not clearly defined .
31-1	3586-3589	The	abstract[198]	giv[198]	_	_
31-2	3590-3594	role	abstract[198]	giv[198]	_	_
31-3	3595-3597	of	abstract[198]	giv[198]	_	_
31-4	3598-3602	pump	abstract[198]|object|abstract[200]	giv[198]|giv|new[200]	coref|coref|coref|coref	32-26|32-26[209_200]|32-26|32-26[209_200]
31-5	3603-3611	exchange	abstract[198]|abstract[200]	giv[198]|new[200]	_	_
31-6	3612-3614	is	_	_	_	_
31-7	3615-3618	not	_	_	_	_
31-8	3619-3626	clearly	_	_	_	_
31-9	3627-3634	defined	_	_	_	_
31-10	3635-3636	.	_	_	_	_

#Text=One study noted a particularly poor prognosis with candidemia and concomitant presence of a cardiac-implanted electronic device , and failure to remove the device during pump exchange was associated with poor outcomes in 65 % of patients .
32-1	3637-3640	One	abstract[201]	new[201]	coref	34-1[219_201]
32-2	3641-3646	study	abstract[201]	new[201]	_	_
32-3	3647-3652	noted	_	_	_	_
32-4	3653-3654	a	abstract[202]	new[202]	_	_
32-5	3655-3667	particularly	abstract[202]	new[202]	_	_
32-6	3668-3672	poor	abstract[202]	new[202]	_	_
32-7	3673-3682	prognosis	abstract[202]	new[202]	_	_
32-8	3683-3687	with	abstract[202]	new[202]	_	_
32-9	3688-3698	candidemia	abstract[202]|event	new[202]|new	_	_
32-10	3699-3702	and	_	_	_	_
32-11	3703-3714	concomitant	abstract[204]	new[204]	_	_
32-12	3715-3723	presence	abstract[204]	new[204]	_	_
32-13	3724-3726	of	abstract[204]	new[204]	_	_
32-14	3727-3728	a	abstract[204]|object[205]	new[204]|new[205]	coref	32-23[207_205]
32-15	3729-3746	cardiac-implanted	abstract[204]|object[205]	new[204]|new[205]	_	_
32-16	3747-3757	electronic	abstract[204]|object[205]	new[204]|new[205]	_	_
32-17	3758-3764	device	abstract[204]|object[205]	new[204]|new[205]	_	_
32-18	3765-3766	,	_	_	_	_
32-19	3767-3770	and	_	_	_	_
32-20	3771-3778	failure	event	new	coref	36-28
32-21	3779-3781	to	_	_	_	_
32-22	3782-3788	remove	_	_	_	_
32-23	3789-3792	the	object[207]	giv[207]	_	_
32-24	3793-3799	device	object[207]	giv[207]	_	_
32-25	3800-3806	during	object[207]	giv[207]	_	_
32-26	3807-3811	pump	object[207]|object|event[209]	giv[207]|giv|giv[209]	coref|coref|coref|coref	36-13|36-24[237_209]|36-13|36-24[237_209]
32-27	3812-3820	exchange	object[207]|event[209]	giv[207]|giv[209]	_	_
32-28	3821-3824	was	_	_	_	_
32-29	3825-3835	associated	_	_	_	_
32-30	3836-3840	with	_	_	_	_
32-31	3841-3845	poor	event[210]	new[210]	coref	38-21[249_210]
32-32	3846-3854	outcomes	event[210]	new[210]	_	_
32-33	3855-3857	in	event[210]	new[210]	_	_
32-34	3858-3860	65	event[210]|quantity[211]	new[210]|new[211]	_	_
32-35	3861-3862	%	event[210]|quantity[211]	new[210]|new[211]	_	_
32-36	3863-3865	of	event[210]|quantity[211]	new[210]|new[211]	_	_
32-37	3866-3874	patients	event[210]|quantity[211]|person	new[210]|new[211]|giv	coref	35-4[226_0]
32-38	3875-3876	.	_	_	_	_

#Text=Some studies have shown that LVAD infections adversely affect survival after adjusting for age and comorbidities .
33-1	3877-3881	Some	event[213]	giv[213]	_	_
33-2	3882-3889	studies	event[213]	giv[213]	_	_
33-3	3890-3894	have	_	_	_	_
33-4	3895-3900	shown	_	_	_	_
33-5	3901-3905	that	_	_	_	_
33-6	3906-3910	LVAD	object|event[215]	giv|giv[215]	coref|coref|coref|coref	35-6[0_215]|36-4|35-6[0_215]|36-4
33-7	3911-3921	infections	event[215]	giv[215]	_	_
33-8	3922-3931	adversely	_	_	_	_
33-9	3932-3938	affect	_	_	_	_
33-10	3939-3947	survival	event	new	_	_
33-11	3948-3953	after	_	_	_	_
33-12	3954-3963	adjusting	_	_	_	_
33-13	3964-3967	for	_	_	_	_
33-14	3968-3971	age	abstract	giv	_	_
33-15	3972-3975	and	_	_	_	_
33-16	3976-3989	comorbidities	abstract	new	_	_
33-17	3990-3991	.	_	_	_	_

#Text=One prospective study showed a 22 % overall infection rate of LVADs and a 5.6-times greater
34-1	3992-3995	One	abstract[219]	giv[219]	_	_
34-2	3996-4007	prospective	abstract[219]	giv[219]	_	_
34-3	4008-4013	study	abstract[219]	giv[219]	_	_
34-4	4014-4020	showed	_	_	_	_
34-5	4021-4022	a	quantity[222]	giv[222]	_	_
34-6	4023-4025	22	quantity[220]|quantity[222]	new[220]|giv[222]	_	_
34-7	4026-4027	%	quantity[220]|quantity[222]	new[220]|giv[222]	_	_
34-8	4028-4035	overall	quantity[222]	giv[222]	_	_
34-9	4036-4045	infection	abstract|quantity[222]	giv|giv[222]	coref	38-8[247_0]
34-10	4046-4050	rate	quantity[222]	giv[222]	_	_
34-11	4051-4053	of	quantity[222]	giv[222]	_	_
34-12	4054-4059	LVADs	quantity[222]|abstract	giv[222]|giv	_	_
34-13	4060-4063	and	_	_	_	_
34-14	4064-4065	a	quantity[224]	new[224]	_	_
34-15	4066-4075	5.6-times	quantity[224]	new[224]	_	_
34-16	4076-4083	greater	quantity[224]	new[224]	_	_

#Text=1-year mortality in patients with infections .
35-1	4084-4090	1-year	abstract[225]	new[225]	coref	36-2[0_225]
35-2	4091-4100	mortality	abstract[225]	new[225]	_	_
35-3	4101-4103	in	abstract[225]	new[225]	_	_
35-4	4104-4112	patients	abstract[225]|person[226]	new[225]|giv[226]	_	_
35-5	4113-4117	with	abstract[225]|person[226]	new[225]|giv[226]	_	_
35-6	4118-4128	infections	abstract[225]|person[226]|event	new[225]|giv[226]|giv	coref	36-4[230_0]
35-7	4129-4130	.	_	_	_	_

#Text=Besides mortality , LVAD infections are associated with a greater risk of pump thrombosis , bleeding complications , prolonged hospitalization , need for pump exchange , and failure to achieve transplantation .
36-1	4131-4138	Besides	_	_	_	_
36-2	4139-4148	mortality	abstract	giv	coref	37-12[243_0]
36-3	4149-4150	,	_	_	_	_
36-4	4151-4155	LVAD	object|event[230]	giv|giv[230]	coref|coref|coref|coref	37-1[241_230]|38-9|37-1[241_230]|38-9
36-5	4156-4166	infections	event[230]	giv[230]	_	_
36-6	4167-4170	are	_	_	_	_
36-7	4171-4181	associated	_	_	_	_
36-8	4182-4186	with	_	_	_	_
36-9	4187-4188	a	abstract[231]	new[231]	_	_
36-10	4189-4196	greater	abstract[231]	new[231]	_	_
36-11	4197-4201	risk	abstract[231]	new[231]	_	_
36-12	4202-4204	of	abstract[231]	new[231]	_	_
36-13	4205-4209	pump	abstract[231]|object|event[233]	new[231]|giv|new[233]	coref|coref	36-24|36-24
36-14	4210-4220	thrombosis	abstract[231]|event[233]	new[231]|new[233]	_	_
36-15	4221-4222	,	_	_	_	_
36-16	4223-4231	bleeding	_	_	_	_
36-17	4232-4245	complications	abstract	new	coref	41-6[256_0]
36-18	4246-4247	,	_	_	_	_
36-19	4248-4257	prolonged	event[235]	new[235]	_	_
36-20	4258-4273	hospitalization	event[235]	new[235]	_	_
36-21	4274-4275	,	_	_	_	_
36-22	4276-4280	need	_	_	_	_
36-23	4281-4284	for	_	_	_	_
36-24	4285-4289	pump	object|event[237]	giv|giv[237]	_	_
36-25	4290-4298	exchange	event[237]	giv[237]	_	_
36-26	4299-4300	,	_	_	_	_
36-27	4301-4304	and	_	_	_	_
36-28	4305-4312	failure	abstract	giv	_	_
36-29	4313-4315	to	_	_	_	_
36-30	4316-4323	achieve	_	_	_	_
36-31	4324-4339	transplantation	event	new	_	_
36-32	4340-4341	.	_	_	_	_

#Text=Bloodstream infections , in particular , are associated with stroke and increased mortality .
37-1	4342-4353	Bloodstream	substance|event[241]	giv|giv[241]	_	_
37-2	4354-4364	infections	event[241]	giv[241]	_	_
37-3	4365-4366	,	event[241]	giv[241]	_	_
37-4	4367-4369	in	event[241]	giv[241]	_	_
37-5	4370-4380	particular	event[241]	giv[241]	_	_
37-6	4381-4382	,	_	_	_	_
37-7	4383-4386	are	_	_	_	_
37-8	4387-4397	associated	_	_	_	_
37-9	4398-4402	with	_	_	_	_
37-10	4403-4409	stroke	event	new	_	_
37-11	4410-4413	and	_	_	_	_
37-12	4414-4423	increased	abstract[243]	giv[243]	_	_
37-13	4424-4433	mortality	abstract[243]	giv[243]	_	_
37-14	4434-4435	.	_	_	_	_

#Text=Despite these risks , the presence of an LVAD infection has not been shown to have a negative impact on post-transplant outcomes .
38-1	4436-4443	Despite	_	_	_	_
38-2	4444-4449	these	abstract[244]	new[244]	_	_
38-3	4450-4455	risks	abstract[244]	new[244]	_	_
38-4	4456-4457	,	_	_	_	_
38-5	4458-4461	the	abstract[245]	new[245]	_	_
38-6	4462-4470	presence	abstract[245]	new[245]	_	_
38-7	4471-4473	of	abstract[245]	new[245]	_	_
38-8	4474-4476	an	abstract[245]|abstract[247]	new[245]|giv[247]	_	_
38-9	4477-4481	LVAD	abstract[245]|object|abstract[247]	new[245]|giv|giv[247]	coref	41-11
38-10	4482-4491	infection	abstract[245]|abstract[247]	new[245]|giv[247]	_	_
38-11	4492-4495	has	_	_	_	_
38-12	4496-4499	not	_	_	_	_
38-13	4500-4504	been	_	_	_	_
38-14	4505-4510	shown	_	_	_	_
38-15	4511-4513	to	_	_	_	_
38-16	4514-4518	have	_	_	_	_
38-17	4519-4520	a	abstract[248]	new[248]	_	_
38-18	4521-4529	negative	abstract[248]	new[248]	_	_
38-19	4530-4536	impact	abstract[248]	new[248]	_	_
38-20	4537-4539	on	abstract[248]	new[248]	_	_
38-21	4540-4555	post-transplant	abstract[248]|event[249]	new[248]|giv[249]	_	_
38-22	4556-4564	outcomes	abstract[248]|event[249]	new[248]|giv[249]	_	_
38-23	4565-4566	.	_	_	_	_

#Text=8.2 .
39-1	4567-4570	8.2	abstract	new	_	_
39-2	4571-4572	.	_	_	_	_

#Text=Gastrointestinal ( GI ) Bleed
40-1	4573-4589	Gastrointestinal	person	new	_	_
40-2	4590-4591	(	_	_	_	_
40-3	4592-4594	GI	abstract	new	coref	41-1
40-4	4595-4596	)	_	_	_	_
40-5	4597-4602	Bleed	_	_	_	_

#Text=GI bleed is one of the most frequent complications after LVAD implant and the most common reason for hospital readmission .
41-1	4603-4605	GI	abstract|event[254]	giv|new[254]	_	_
41-2	4606-4611	bleed	event[254]	new[254]	_	_
41-3	4612-4614	is	_	_	_	_
41-4	4615-4618	one	abstract[255]	new[255]	_	_
41-5	4619-4621	of	abstract[255]	new[255]	_	_
41-6	4622-4625	the	abstract[255]|abstract[256]	new[255]|giv[256]	_	_
41-7	4626-4630	most	abstract[255]|abstract[256]	new[255]|giv[256]	_	_
41-8	4631-4639	frequent	abstract[255]|abstract[256]	new[255]|giv[256]	_	_
41-9	4640-4653	complications	abstract[255]|abstract[256]	new[255]|giv[256]	_	_
41-10	4654-4659	after	abstract[255]|abstract[256]	new[255]|giv[256]	_	_
41-11	4660-4664	LVAD	abstract[255]|abstract[256]|abstract|object[258]	new[255]|giv[256]|giv|new[258]	coref|coref	43-20|43-20
41-12	4665-4672	implant	abstract[255]|abstract[256]|object[258]	new[255]|giv[256]|new[258]	_	_
41-13	4673-4676	and	_	_	_	_
41-14	4677-4680	the	abstract[259]	new[259]	ana	42-1[0_259]
41-15	4681-4685	most	abstract[259]	new[259]	_	_
41-16	4686-4692	common	abstract[259]	new[259]	_	_
41-17	4693-4699	reason	abstract[259]	new[259]	_	_
41-18	4700-4703	for	abstract[259]	new[259]	_	_
41-19	4704-4712	hospital	abstract[259]|place|abstract[261]	new[259]|new|new[261]	_	_
41-20	4713-4724	readmission	abstract[259]|abstract[261]	new[259]|new[261]	_	_
41-21	4725-4726	.	_	_	_	_

#Text=It is triggered by the use of antiplatelet and anticoagulant therapy .
42-1	4727-4729	It	abstract	giv	_	_
42-2	4730-4732	is	_	_	_	_
42-3	4733-4742	triggered	_	_	_	_
42-4	4743-4745	by	_	_	_	_
42-5	4746-4749	the	abstract[263]	new[263]	_	_
42-6	4750-4753	use	abstract[263]	new[263]	_	_
42-7	4754-4756	of	abstract[263]	new[263]	_	_
42-8	4757-4769	antiplatelet	abstract[263]|substance	new[263]|new	_	_
42-9	4770-4773	and	_	_	_	_
42-10	4774-4787	anticoagulant	abstract|abstract[266]	new|new[266]	_	_
42-11	4788-4795	therapy	abstract[266]	new[266]	_	_
42-12	4796-4797	.	_	_	_	_

#Text=Additionally , CF-LVADs can cause acquired von Willebrand factor deficiency due to the high shear stress imposed by the LVAD motor , resulting in breakdown of large von Willebrand factor multimers .
43-1	4798-4810	Additionally	_	_	_	_
43-2	4811-4812	,	_	_	_	_
43-3	4813-4821	CF-LVADs	substance	new	_	_
43-4	4822-4825	can	_	_	_	_
43-5	4826-4831	cause	_	_	_	_
43-6	4832-4840	acquired	_	_	_	_
43-7	4841-4844	von	abstract	new	coref	43-28
43-8	4845-4855	Willebrand	substance|abstract[271]	new|new[271]	coref|coref	43-29|43-29
43-9	4856-4862	factor	abstract|abstract[271]	new|new[271]	coref	43-28[279_0]
43-10	4863-4873	deficiency	abstract[271]	new[271]	_	_
43-11	4874-4877	due	_	_	_	_
43-12	4878-4880	to	_	_	_	_
43-13	4881-4884	the	abstract[273]	new[273]	_	_
43-14	4885-4889	high	abstract[273]	new[273]	_	_
43-15	4890-4895	shear	place|abstract[273]	new|new[273]	_	_
43-16	4896-4902	stress	abstract[273]	new[273]	_	_
43-17	4903-4910	imposed	_	_	_	_
43-18	4911-4913	by	_	_	_	_
43-19	4914-4917	the	abstract[275]	new[275]	_	_
43-20	4918-4922	LVAD	place|abstract[275]	giv|new[275]	_	_
43-21	4923-4928	motor	abstract[275]	new[275]	_	_
43-22	4929-4930	,	_	_	_	_
43-23	4931-4940	resulting	_	_	_	_
43-24	4941-4943	in	_	_	_	_
43-25	4944-4953	breakdown	event[276]	new[276]	_	_
43-26	4954-4956	of	event[276]	new[276]	_	_
43-27	4957-4962	large	event[276]|object[280]	new[276]|new[280]	_	_
43-28	4963-4966	von	event[276]|abstract|abstract[279]|object[280]	new[276]|giv|giv[279]|new[280]	_	_
43-29	4967-4977	Willebrand	event[276]|abstract|abstract[279]|object[280]	new[276]|giv|giv[279]|new[280]	_	_
43-30	4978-4984	factor	event[276]|abstract[279]|object[280]	new[276]|giv[279]|new[280]	_	_
43-31	4985-4994	multimers	event[276]|object[280]	new[276]|new[280]	_	_
43-32	4995-4996	.	_	_	_	_

#Text=Also , continuous flow physiology and dysregulation of angiogenic factors have been shown to lead to development of arteriovenous malformations ( AVMs ) in the gastrointestinal tract , nasopharynx , brain , and other tissues .
44-1	4997-5001	Also	_	_	_	_
44-2	5002-5003	,	_	_	_	_
44-3	5004-5014	continuous	abstract[282]	new[282]	_	_
44-4	5015-5019	flow	abstract|abstract[282]	new|new[282]	_	_
44-5	5020-5030	physiology	abstract[282]	new[282]	_	_
44-6	5031-5034	and	_	_	_	_
44-7	5035-5048	dysregulation	abstract[283]	new[283]	_	_
44-8	5049-5051	of	abstract[283]	new[283]	_	_
44-9	5052-5062	angiogenic	abstract[283]|abstract|abstract[285]	new[283]|new|new[285]	_	_
44-10	5063-5070	factors	abstract[283]|abstract[285]	new[283]|new[285]	_	_
44-11	5071-5075	have	_	_	_	_
44-12	5076-5080	been	_	_	_	_
44-13	5081-5086	shown	_	_	_	_
44-14	5087-5089	to	_	_	_	_
44-15	5090-5094	lead	_	_	_	_
44-16	5095-5097	to	_	_	_	_
44-17	5098-5109	development	event[286]	new[286]	_	_
44-18	5110-5112	of	event[286]	new[286]	_	_
44-19	5113-5126	arteriovenous	event[286]|person|abstract[288]	new[286]|new|new[288]	appos|appos	44-22[0_288]|44-22[0_288]
44-20	5127-5140	malformations	event[286]|abstract[288]	new[286]|new[288]	_	_
44-21	5141-5142	(	_	_	_	_
44-22	5143-5147	AVMs	abstract	giv	_	_
44-23	5148-5149	)	_	_	_	_
44-24	5150-5152	in	_	_	_	_
44-25	5153-5156	the	object[290]	new[290]	_	_
44-26	5157-5173	gastrointestinal	object[290]	new[290]	_	_
44-27	5174-5179	tract	object[290]	new[290]	_	_
44-28	5180-5181	,	_	_	_	_
44-29	5182-5193	nasopharynx	place	new	_	_
44-30	5194-5195	,	_	_	_	_
44-31	5196-5201	brain	object	new	_	_
44-32	5202-5203	,	_	_	_	_
44-33	5204-5207	and	_	_	_	_
44-34	5208-5213	other	place[293]	new[293]	_	_
44-35	5214-5221	tissues	place[293]	new[293]	_	_
44-36	5222-5223	.	_	_	_	_
